Natural Product (NP) Details
| General Information of the NP (ID: NP2556) | |||||
|---|---|---|---|---|---|
| Name |
Anisodamine
|
||||
| Synonyms |
anisodamine; UNII-01343Q8EL8; 01343Q8EL8; 6-Hydroxy hyoscyamine; 55869-99-3; 6-Hydroxyhyoscyamine; 654-II; (Z)-RACANISODAMINE; CHEMBL2165224; HY-N0584; ZINC3197739; AKOS015955736; CCG-221772; CS-4549; DB11785; MCULE-3459933530; Hyoscyamine, 6-hydroxy- (6CI, 7CI); NCGC00485098-01; NCGC00485098-02; UNII-QQZ59S1DUT component WTQYWNWRJNXDEG-RBZJEDDUSA-N; (S)-3-hydroxy-2-phenyl-propionic acid (1r,3s,5r,6S)-6-hydroxy-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl ester, AldrichCPR; [(1R,3S,5R,6S)-6-hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] (2S)-3-hydroxy-2-phenylpropanoate; alpha-(Hydroxymethyl)benzeneacetic acid 6-hydroxy-8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester; Benzeneacetic acid, alpha-(hydroxymethyl)-, (1R,3S,5R,6S)-6-hydroxy-8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester, (alphaS)-; Benzeneacetic acid, alpha-(hydroxymethyl)-, 6-hydroxy-8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester, (1R-(1-alpha,3-beta(S*),5-alpha,6-alpha))-
Click to Show/Hide
|
||||
| Species Origin | Solanaceae ... | Click to Show/Hide | |||
| Solanaceae | |||||
| Disease | Central and peripheral nervous disease [ICD-11: 8A04-8E7Z] | Approved | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C17H23NO4
|
||||
| PubChem CID | |||||
| Canonical SMILES |
CN1C2CC(CC1C(C2)O)OC(=O)C(CO)C3=CC=CC=C3
|
||||
| InChI |
1S/C17H23NO4/c1-18-12-7-13(9-15(18)16(20)8-12)22-17(21)14(10-19)11-5-3-2-4-6-11/h2-6,12-16,19-20H,7-10H2,1H3/t12-,13-,14+,15+,16-/m0/s1
|
||||
| InChIKey |
WTQYWNWRJNXDEG-RBZJEDDUSA-N
|
||||
| CAS Number |
CAS 55869-99-3
|
||||
| Herb ID | |||||
| SymMap ID | |||||
| TCMSP ID | |||||
| TTD Drug ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| Neostigmine | Myasthenia gravis | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | JAK-2 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | STAT3 | Molecule Info |
Pathway MAP
|
||
| In-vivo Model | SD rats (250-270 g), C57BL/6 mice (25-30 g), and rabbits (2-3 kg) CS models were used in this study. | |||||
| Experimental
Result(s) |
Ani/Neo combination could produce therapeutic effects in CS. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Adrenergic receptor beta-1 (ADRB1) | Molecule Info | [3] | |
| KEGG Pathway | Calcium signaling pathway | Click to Show/Hide | ||
| 2 | cGMP-PKG signaling pathway | |||
| 3 | cAMP signaling pathway | |||
| 4 | Neuroactive ligand-receptor interaction | |||
| 5 | Endocytosis | |||
| 6 | Adrenergic signaling in cardiomyocytes | |||
| 7 | Gap junction | |||
| 8 | Salivary secretion | |||
| 9 | Dilated cardiomyopathy | |||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | Click to Show/Hide | ||
| 2 | Beta1 adrenergic receptor signaling pathway | |||
| Pathwhiz Pathway | Muscle/Heart Contraction | Click to Show/Hide | ||
| Reactome | Adrenoceptors | Click to Show/Hide | ||
| 2 | G alpha (s) signalling events | |||
| WikiPathways | Monoamine GPCRs | Click to Show/Hide | ||
| 2 | Calcium Regulation in the Cardiac Cell | |||
| 3 | GPCRs, Class A Rhodopsin-like | |||
| 4 | Endothelin Pathways | |||
| 5 | GPCR ligand binding | |||
| 6 | GPCR downstream signaling | |||
